ISL
IOVA icon

Ingalls & Snyder LLC’s Iovance Biotherapeutics IOVA Stock Holding History

Ingalls & Snyder LLC’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62K Buy
+15,000
New +$57K ﹤0.01% 464

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Ingalls & Snyder LLC's IOVA Position: Q2 2026 in Review

Ingalls & Snyder LLC opened a new position in Iovance Biotherapeutics (IOVA) in Q2 2026: 15,000 shares worth $62K. The stake represents ﹤0.01% of the portfolio and ranks #464 among its holdings.

292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Ingalls & Snyder LLC held 15,000 shares of Iovance Biotherapeutics worth $62K as of Q2 2026.
  • Iovance Biotherapeutics was a new Ingalls & Snyder LLC position in Q2 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of Ingalls & Snyder LLC's portfolio in Q2 2026, its #464 holding.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Ingalls & Snyder LLC's 13F filing for Q2 2026, filed 14 Aug 2026.